Company Overview
Indorama Ventures Hygiene Denmark A/S is a low-profile Danish manufacturer of hygiene-related nonwovens and components, operating from a single EU facility. With revenue below €10 m, the business supplies private-label and contract volumes to regional personal-care and medical customers. Scale is modest, with an implied EBITDA margin likely in the 9–12 % range based on Baltic hygiene and materials peers, though exact figures remain undisclosed in public filings.
Deal Context
The asset appears to be a non-core divestiture by Indorama Ventures, creating a classic strategic tuck-in opportunity. A Baltic or Nordic industrial buyer could secure capacity, customer contracts and regulatory compliance at a fraction of greenfield cost. PE interest is limited given size and opacity; instead, expect inbound from mid-sized converters or packaging groups seeking EU footprint without Baltic wage arbitrage.
Valuation Context
Baltic listed peers trade at a 5–9× EV/EBITDA median (excluding outliers), equating to roughly 0.6–1.2× revenue at prevailing margins. Applying a 35–45 % private-company discount for illiquidity, key-man concentration and sub-€10 m revenue yields a realistic 3.5–5.5× EBITDA or 0.4–0.7× revenue entry multiple. This leaves headroom for a strategic rerating toward 7–8× on proven integration.
Triage Verdict
REVIEW
- Fit: Sector and EU manufacturing location align with thesis; size and margin profile sit within Baltic peer envelope.
- Red flags: Opaque revenue base and minimal disclosed customer overlap raise diligence friction; limited public track record increases execution risk.
- Next step: Request three-year statutory accounts and customer concentration schedule from Erhvervsstyrelsen before deciding on outreach.
Key Risk
Customer or contract loss post-carve-out could erase the thin margin cushion implied by Baltic benchmarks.
Bottom line: modest strategic value at a steep discount, but only after revenue transparency is secured.
| # | Fund | AUM | YTD | Positions |
|---|---|---|---|---|
| 1 | Ma Investment Partnership, LP | $322.6B | +150.2% | 18 |
| 2 | Anther Capital Ltd | $3.8T | +125.9% | 31 |
| 3 | Central Asset Investments & Manag… | $261.4B | +118.1% | 63 |
| 4 | Shengqi Capital (Hong Kong) Ltd | $95.6B | +117.7% | 10 |
| 5 | Oxbow Capital Management (HK) Ltd | $731.4B | +105.7% | 14 |
| 6 | Graticule Asia Macro Advisors LLC | $1.1T | +93.9% | 4 |
| 7 | AIHC Capital Management Ltd | $226.4B | +90.5% | 11 |
| 8 | Grand Alliance Asset Management Ltd | $302.6B | +90.0% | 24 |
| 9 | Amanah Holdings Trust | $1.6T | +87.7% | 40 |
| 10 | E20 Capital Ltd | $1.3T | +86.9% | 42 |
| Security | Value | Weight |
|---|---|---|
| MICRON TECHNOLOGY INC | $67.6B | 70.7% |
| PALANTIR TECHNOLOGIES INC | $27.9B | 29.2% |
| ALPHABET INC | $28.7M | 0.0% |
| ALPHABET INC | $28.7M | 0.0% |
| PROSHARES TR | $8.3M | 0.0% |
| Company | Ticker | Exchange | Expected | Deal Value |
|---|---|---|---|---|
| SpaceX | SPCX | NASDAQ | 2026-06-12 | — |
| Research Alliance Corp IV | RACD | UNKNOWN | TBD | $75.0M |
| Sin Lian Seng Construction | ININ | UNKNOWN | TBD | $35.9M |
| Attovia Therapeutics, Inc. | ATTO | UNKNOWN | TBD | $100.0M |
| Cartesian Growth Corp IV | CGCFU | UNKNOWN | TBD | $287.5M |
| Company | Sector | Valuation |
|---|---|---|
| Anthropic | Artificial Intelligence | $965.0B |
| OpenAI | Artificial Intelligence | $894.3B |
| Stripe | Financial Services | $180.0B |